Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice

British Journal of Nutrition

Volumn 111, Issue 6, 2014, Pages 987-995

  Wang, Honggang ^a   Dong, Jianning ^a   Zuo, Lugen ^a   Liu, Jianhui ^a   Zhu, Weiming ^a   Li, Yi ^a   Gu, Lili ^a   Zhao, Jie ^a   Zhang, Liang ^a   Gong, Jianfeng ^a   Zhang, Wei ^a   Li, Ning ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

CD52 monoclonal antibody; IL 10 knockout mice; Inflammatory bowel disease; Iron deficient anaemia

Indexed keywords

ALEMTUZUMAB; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 10; IRON; MESSENGER RNA; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFERRIN; CD4 ANTIGEN; CD45 ANTIGEN; CD52 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PTPRC PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON STORAGE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING; ANIMAL; BLOOD; C3H MOUSE; CHEMISTRY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER; PHYSIOLOGY; WEIGHT REDUCTION;

MUS;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, CD45; ANTIGENS, NEOPLASM; COLITIS; ERYTHROPOIETIN; GLYCOPROTEINS; HEMOGLOBINS; HEPCIDINS; INTERLEUKIN-10; LIVER; LYMPHOCYTE COUNT; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; RNA, MESSENGER; T-LYMPHOCYTES; WEIGHT LOSS;

EID: 84899689659     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114513003413     Document Type: Article

References (42)

1. Ordas I, Eckmann L, Talamini M, et al. (2012) Ulcerative colitis. Lancet 380, 1606-1619.
2. Tyagi A, Kumar U, Reddy S, et al. (2012) Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with alpha-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr 108, 1612-1622.
3. (-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258, 256-267.
4. Goodhand JR, Kamperidis N, Rao A, et al. (2012) Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 18, 513-519.
5. Carter PR, Watts MN, Kosloski-Davidson M, et al. (2013) Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis. Inflamm Bowel Dis 19, 1260-1265.
6. Lomer MC, Cook WB, Jan-Mohamed HJ, et al. (2012) Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr 107, 1806-1811.
7. Stein J, Hartmann F & Dignass AU (2010) Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 7, 599-610.
8. Berg DJ, Zhang J, Weinstock JV, et al. (2002) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123, 1527-1542.
9. Ouyang W, Rutz S, Crellin NK, et al. (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29, 71-109.
10. Kuhn R, Lohler J, Rennick D, et al. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274.
11. Kaser A, Zeissig S & Blumberg RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28, 573-621.
12. Hentze MW, Muckenthaler MU, Galy B, et al. (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142, 24-38.
13. Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. (2011) Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol 23, 262-268.
14. Wang L, Trebicka E, Fu Y, et al. (2012) The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 18, 112-119.
15. Babitt JL, Huang FW, Xia Y, et al. (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117, 1933-1939.
16. Maloy KJ & Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298-306.
17. MacDonald TT, Biancheri P, Sarra M, et al. (2012) What's the next best cytokine target in IBD. Inflamm Bowel Dis 18, 2180-2189.
18. Jones JL, Phuah CL, Cox AL, et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119, 2052-2061.
19. Rao SP, Sancho J, Campos-Rivera J, et al. (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLOS ONE 7, e39416.
20. Qu L, Li Q, Jiang H, et al. (2009) Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes. Transplantation 88, 766-772.
21. Coles AJ, Twyman CL, Arnold DL, et al. (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829-1839.
22. Scheinberg P, Nunez O, Weinstein B, et al. (2012) Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 119, 345-354.
23. Zhu WM, Li Y, Yu C, et al. (2011) Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice. Inflamm Bowel Dis 17, E72-E73.
24. Berg DJ, Davidson N, Kuhn R, et al. (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98, 1010-1020.
25. Li Y, Yu C, Zhu WM, et al. (2010) Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and downregulation of IL-17. Mol Immunol 47, 2467-2474.
26. Cuzzocrea S, Mazzon E, Di PR, et al. (2004) Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther 311, 1272-1280.
27. Katsanos KH, Tatsioni A, Natsi D, et al. (2012) Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: a 15-year single center experience. J Crohns Colitis 6, 56-61.
28. Baumgart DC & Sandborn WJ (2012) Crohn's disease. Lancet 380, 1590-1605.
29. Liu B, Tonkonogy SL & Sartor RB (2011) Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology 141, 653-662, 662.e1-662.e4.
30. Gasche C, Reinisch W, Lochs H, et al. (1994) Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 39, 1930-1934.
31. Nairz M, Schroll A, Moschen AR, et al. (2011) Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 34, 61-74.
32. Nairz M, Sonnweber T, Schroll A, et al. (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14, 238-246.
33. Nemeth E, Tuttle MS, Powelson J, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093.
34. Zhang DL, Senecal T, Ghosh MC, et al. (2011) Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood 118, 2868-2877.
35. Qiao B, Sugianto P, Fung E, et al. (2012) Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab 15, 918-924.
36. Wang L, Harrington L, Trebicka E, et al. (2009) Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 119, 3322-3328.
37. Shanmugam NK, Ellenbogen S, Trebicka E, et al. (2012) Tumor necrosis factor alpha inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis. PLOS ONE 7, e38136.
38. Zhao N, Zhang AS & Enns CA (2013) Iron regulation by hepcidin. J Clin Invest 123, 2337-2343.
39. Pietrangelo A, Dierssen U, Valli L, et al. (2007) STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132, 294-300.
40. Song SN, Tomosugi N, Kawabata H, et al. (2010) Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116, 3627-3634.
41. Andriopoulos B Jr, Corradini E, Xia Y, et al. (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41, 482-487.
42. Babitt JL, Huang FW, Wrighting DM, et al. (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38, 531-539.